Treatment of Head and Neck Cancers with BRMs

Biotherapy

Volumn 10, Issue 2, 1997, Pages 115-120

  Yoshida, Tomoyuki ^a   Saeki, Tetsuro ^a   Aoyama, Yumiko ^a   Okudaira, Tadao ^a   Okada, Takuya ^a   Funasaka, Sotaro ^a  

^a Tokyo Medical University   (Japan)

Author keywords

BRM; Head and neck cancer; Lentinan; Prolongation of survival; Sizofiran

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOSUPPRESSIVE ACID PROTEIN; LENTINAN; SCHIZOPHYLLAN;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; IMMUNITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SURVIVAL TIME;

AGED; ANTIGENS, NEOPLASM; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SERPINS; SURVIVAL ANALYSIS;

EID: 0030824229     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678538     Document Type: Article

References (34)

1. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from lentinus edoes (Berk.) Sing. Nature 1969; 222: 687-688.
2. Fujimoto S, Okui K. Sizofilan. (Japanese) Saishin Igaku 1987; 42: 300-307.
3. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Slat Assoc 1958; 53:457-481.
4. GehanEA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52:203-223.
5. Gehan EA. Statistical methods for survival time studies, in Cancer therapy: Prognostic factors and criteria of response, edited by M. J. Staquet. Raven Press, New York, 1975 p7-35
6. Cox DR. Regression models and life tables. J R Stat Soc(B) 1972; 34: 187-220.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
8. Orita K, Miwa H, Kawai T. Blastogenesis . (Japanese) Can no Rinsho (Jpn J Cancer Clin) 1978; 24:941-947.
9. Kamei H. Immunological parameters in cancer bearing patients after treatment with immunostimulants. (Japanese) Can no Rinsho (Jpn J Cancer Clin) 1978; 24: 948-955.
10. Hamuro J, Takarada M, Kasima N, Mitsugi K. Lentinan induced augmented killer T cell generation from thymocytes is due to the elevated susceptibility to helper factors). (Abstract) Int J Immunopharmacol 1980; 2: 171.
11. Akiyama Y, Hamuro J. Effect of Antitumor Polysaccharides on Specific and Nonspecific Immune Responses and Their Immunological Characteristics. (Japanese) Tanpakushitsu Kakusan Koso (Protein Nucleic Acid and Enzyme) 1981; 26: 208-224.
12. Mitani M, Iwano K, Arika T, Kikuchi M. Immunochemotherapy of syngeneic murine tumors with an immunopotentiator schizophyllan. (Japanese) Can to Kagaku Ryoho (Jpn J Cancer Chemother) 1982; 9:122-128.
13. Matsuo T, Arika T, Asano T, Mitsuya M. Activity of schizophyllan (SPC), an antitumor polysaccharide, for enhancement of immunological competence of host. (Japanese) Yakuri to Chiryo (Jpn Pharmacol Therap) 1981; 9: 1835-1843.
14. Tsuchiya Y, Yamamoto M, Igarashi M, Suzuki R, Kumagai K. Study on immunomodulating activity of an antitumor glucan, sizofilan at humoral factor level. (Japanese) Rinsho Meneki (Clin immunol) 1986; 18: 575-584.
15. Takahashi M, Takai M, Ogawa M, Ono K, Endo F, Masuda Y, Ogata A, Uno F, Obata G. Lymphocyte subsets in thé patients with gastric cancer and effects of Lentinan - Evaluation by two-color flow cytometry -. (Japanese) Biotherapy 1988; 2: 403-408.
16. Oka T, Miwa H, Ono M, Kobayashi T, Gochi A, Nakamura K, Orita K. Antitumor effect and influence of schizophyllan (SPG) on ADCC and NK activities in C3H/He mice transplanted MH134 tumors. (Japanese) Kiso to Rinsho (Clin Rep) 1982; 16: 3989-39%.
17. Kikuchi M, Iwano K, Numasaki Y, Komuro K. Augmented induction of ADCC and NK cell activities by schizophyllan
18. (SPC), an antitumor polysaccharide. (Japanese) Kinki Daigaku Igaku Zasshi (Med J Kinki Univ) 1981; 6: 375-381.
19. Shimizu Y, Chen JT, Hirai Y, Teshima H, Nakayama K, Hamada T, Fujimoto I, Yamauchi K, Hasumi K, Masubuchi K. Augmentative Effect of Lentinan on Interleukin-2 Production and Lymphokine-activated Killer Cell Activity in Pelvic Lymph Node lymphocytes from Patients with Cervical Cancer. (Japanese) Igaku no Ayumi 1988; 147: 137-138.
20. Yoneyama A, Nakahara K. Diagnosis of Lymphotic Tumors by Monoclonal Antibody. (Japanese) Biomedica 1987; 2:156161.
21. Takase K. Two-color analysis with flow cytometry. (Japanese) Rinsho Meneki (Clin immunol) 1986; 18: 253-260.
22. Clement LT Grossi CE, Gartland GL. Morphologic and phenotypic features of the subpopulation of Leu2+ cells that suppresses B cell differentiation. J Immunol 1984; 133: 24612468.
23. Furusaka T, Yokode Y, Nakajima M, lida H, Kida A, Kikuchi K, Tomita H. T lymphocyte subsets in patients with squamous cell carcinoma of the head and neck. Auris Nasus Larynx 1986; 13Suppl 1:S143-S148.
24. Abo T, Miller CA and Batch cm. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults. Eur J Immunol 1984; 14: 616623.
25. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7(HNK-1) and Leu-11(NK-15) antigens. JImmunol 1983; 131: 1789-1796.
26. Matsuda Y, Motoki H, Kitame F. Ishida N. Immunosuppressive acidic protein found in tumor-bearing mouse serum. (Japanese) Igaku no Ayumi 1977; 102: 747-749.
27. Matsuda Y, Tainura K, Kitame F, Ishida N. Physicochemical and immunosuppressive properties of immunosupressive acidic protein (IAP) isolated from the serum of cancer patient. (Japanese) Igaku no Ayumi 1978; 105: 154-157.
28. Shibata Y, Ishida N. Macrophage function in tumor-bearing mice in correlation with IAP increase in serum. (Japanese) Igaku no Ayumi 1983; 126: 631-634.
29. Furue H, Komita T, Hakozaki M, Kobayashi H, Motoki H, Yata J, Shimbo T. Immunological parameters during cancer chemotherapy and or immunotherapy third report. Immunosuppressive acidic protein. (Japanese) Can to Kagaku Ryoho (Jpn J Cancer Chemother) 1980; 7: 223-230.
30. Saito H, Hozawa J, Mon I, Fukuoka K. Observation on immunosuppressive acidic protein (IAP) in treatment of head and neck cancer. (Japanese) Jibiinkoka Rinsho (Pract Otol) 1984; 77: 1481-1488.
31. Yamanaka N, Harabuchi Y, Himi T, Kataura A. Immunosuppresive substance in the sera of head and neck cancer patients. Cancer 1988; 62: 1293-1298.
32. Okudaira T. Biological response modifier therapy for head and neck cancer. (Japanese) Jibiinkoka Rinsho (Pract Otol) 1992; 85: 283-292.
33. Okada T, Yoshida T, Saeki T, Aoyama Y, Okudaira T, Funasaka S. Immunological influence of sizoflran in patients with cancer of the head. (Japanese) Jibi to Rinsho (Otol Fukuoka) 1990; 36: 1200-1206.
34. Ohashi S, Yoshida T, Okudaira T, Araki S, Sato H, Yoshiura H, Kitamura M, Hagiwara A, Sasaya F, Funasaka S. Changes in immunological parameters at the time of reccurrent in patients with head and neck cancers. (Japanese) Jibi Inkoka Tenbo (O.R.L. Tokyo) 1994; 37: 333-340.